Jürgen Hemberger

Title: Jürgen Hemberger: Innovator in Platelet Adhesion Inhibition

Introduction

Jürgen Hemberger is a notable inventor based in Aschaffenburg, Germany. He has made significant contributions to the field of biomedical research, particularly in the area of platelet adhesion. His work has implications for therapeutic treatments related to heart disease and circulation disorders.

Latest Patents

Hemberger holds a patent for a naturally occurring protein that blocks platelet adhesion. This protein, isolated from the saliva of the medicinal leech, binds strongly to collagen, acting as an inhibitor of natural platelet adhesion. The protein has a molecular weight of about 12,000 and features an acidic isoelectric point, containing six cysteines. The sequencing of the protein and cloning of its gene from a cDNA library have been accomplished. The procedures for producing this polypeptide through recombinant techniques are also disclosed in his patent. Both the recombinant and naturally occurring proteins serve as potent inhibitors of collagen-dependent platelet adhesion, making them useful for treating various conditions related to heart disease and the circulatory system.

Career Highlights

Hemberger is associated with Merck Patent GmbH, where he continues to advance his research and innovations. His work has garnered attention for its potential applications in medical treatments and device coatings.

Collaborations

Hemberger has collaborated with notable colleagues, including Wolfgang Strittmatter and Detlef Güssow. Their combined expertise has contributed to the development of innovative solutions in the field of platelet adhesion.

Conclusion

Jürgen Hemberger's contributions to the understanding and inhibition of platelet adhesion represent a significant advancement in biomedical research. His patented protein offers promising therapeutic applications, highlighting the importance of innovation in addressing health challenges.